Streetbeat News

Stock Prices

NVCR

NovoCure reported better-than-expected Q3 2024 results with a GAAP EPS of $(0.28), beating the estimate of $(0.33), and sales of $155.09M, surpassing the $143.95M estimate. Sales increased by 21.81% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:01 am

DAN

Dana Inc. reported Q3 2024 earnings per share of $0.12, missing the analyst estimate of $0.23. Sales were $2.476 billion, below the expected $2.589 billion and down 7.23% from last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:00 am

SW

Smurfit WestRock reported a Q3 2024 GAAP EPS of $(0.30), missing the analyst estimate of $0.76 by 139.47%. Quarterly sales were $7.67 billion, below the expected $8.20 billion, but up 163.16% from last year's $2.92 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:59 am

MLM

Martin Marietta Materials reported Q3 2024 earnings per share of $5.91, missing the analyst estimate of $6.32. Sales were $1.889 billion, below the expected $1.934 billion. Both earnings and sales decreased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:57 am

GPN

Global Payments reported its Q3 2024 financial results, with adjusted EPS of $3.08 and adjusted sales of $2.357 billion, both missing analyst estimates of $3.12 and $2.381 billion, respectively.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:56 am

EXC

Exelon has reaffirmed its 2024 earnings outlook, projecting adjusted EPS between $2.40 and $2.50, aligning closely with the $2.45 estimate. The company reported strong Q3 performance with adjusted operating earnings of $0.71 per share.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:56 am

LLY

Eli Lilly's shares declined following the release of disappointing Q3 earnings and sales figures.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:53 am

LLY

Eli Lilly has revised its 2024 adjusted EPS forecast to $13.02-$13.52, down from the previous guidance of $16.10-$16.60, and close to the consensus of $13.47. This adjustment is due to acquired IPR&D charges incurred in Q3.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:52 am

BIIB

Biogen reported Q3 2024 earnings per share of $4.08, surpassing the analyst estimate of $3.79, despite a year-over-year decrease. Sales were $2.47 billion, also beating expectations but down from last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:51 am

SPRO

Spero Therapeutics' shares declined following the announcement that their Phase 2a study of SPR720 failed to meet its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:49 am